Zandelisib is an orally bioavailable inhibitor of the delta isoform of phosphatidylinositide 3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, zandelisib selectively inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. PI3K-delta plays a key role in the proliferation and survival of hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include ACC-524, PW-143 and 8Z28M5SX0X. Its PubChem CID is 66571003.
Zandelisib
| CAS No | 1401436-95-0 |
|---|---|
| Molecular Formula | C31H38F2N8O |
| Molecular Weight | 576.70 g/mol |
| Synonyms | 4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Zandelisib is an orally bioavailable inhibitor of the delta isoform of phosphatidylinositide 3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, zandelisib selectively inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway.
The listed CAS number is 1401436-95-0.
The listed molecular formula is C31H38F2N8O.
The listed molecular weight is 576.70 g/mol.
4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine.
The source lists ACC-524, PW-143 and 8Z28M5SX0X.